Ecabet

• Description :

  Ecabet sodium (TA-2711) is currently applied to some clinical gastrointestinal disease by inhibiting the ROS production and improving Helicobacter pylori eradication[1]. Ecabet sodium reduces apoptosis[2]

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Bacterial; Reactive Oxygen Species (ROS)

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/ecabet.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C([C@]1(C)CCC[C@]2(C)C3=C(CC[C@@]12[H])C=C(C(C)C)C(S(=O)(O)=O)=C3)O

• Molecular Formula :

  C20H28O5S

• Molecular Weight :

  380.50

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Wang Y, et al. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2014 Oct;19 (5) :372-81.|[2]Rah YC, et al. Ecabet sodium alleviates neomycin-induced hair cell damage. Free Radic Biol Med. 2015 Dec;89:1176-83.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [33159-27-2]